Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Applied Molecular Transport Inc. AMTI
$0.26
-$0.02 (-7.68%)
На 17:47, 12 мая 2023
+1 053.85%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
11309489.00000000
-
week52high
4.58
-
week52low
0.21
-
Revenue
0
-
P/E TTM
0
-
Beta
1.97982300
-
EPS
-2.68000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Hold | Buy | 07 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 мая 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 мая 2022 г. |
| JMP Securities | Outperform | 17 мар 2021 г. | |
| SVB Leerink | Outperform | Outperform | 08 ноя 2022 г. |
| B of A Securities | Underperform | Buy | 05 янв 2023 г. |
| SVB Leerink | Market Perform | Outperform | 27 дек 2022 г. |
| JMP Securities | Market Perform | Market Outperform | 23 дек 2022 г. |
| Chardan Capital | Buy | 02 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cross Shawn | D | 61090 | 3893 | 02 дек 2022 г. |
| Hants Brandon | D | 32819 | 1959 | 02 дек 2022 г. |
| Kanwar Bittoo | D | 78544 | 3488 | 02 дек 2022 г. |
| Mahmood Tahir Ph.D. | D | 75428 | 1772 | 02 дек 2022 г. |
| Mrsny Randall Ph.D. | D | 21136 | 418 | 02 дек 2022 г. |
| Rich Douglas A. | D | 49798 | 4229 | 02 дек 2022 г. |
| VanDevender Aaron | A | 212659 | 50000 | 28 ноя 2022 г. |
| VanDevender Aaron | A | 162659 | 100000 | 25 ноя 2022 г. |
| Rich Douglas A. | D | 54027 | 448 | 01 сент 2022 г. |
| Mrsny Randall Ph.D. | D | 21554 | 404 | 01 сент 2022 г. |
Новостная лента
Applied Molecular Transport to Present at Upcoming November Investor Conferences
GlobeNewsWire
08 ноя 2022 г. в 08:00
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation at the following investor conferences:
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
GlobeNewsWire
05 июл 2022 г. в 16:01
Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT) Live Conference Call and Webcast on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT)
Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs
Benzinga
18 мая 2022 г. в 12:48
Applied Molecular Transport Inc (NASDAQ: AMTI) will prioritize the advancement of AMT-101 into late-stage clinical development. It is preparing for the end of Phase 2 meetings with the FDA to advance AMT-101 to Phase 3 in chronic pouchitis.
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
GlobeNewsWire
05 мая 2022 г. в 16:01
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET (11:20 a.m. PT).